Drug Shortage Report for TEVA-ATAZANAVIR

Last updated on 2020-07-23 History
Report ID 111813
Drug Identification Number 02443821
Brand name TEVA-ATAZANAVIR
Common or Proper name ATAZANAVIR SULF 300MG CAPSULE
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) ATAZANAVIR
Strength(s) 300MG
Dosage form(s) CAPSULE
Route of administration ORAL ORAL
Packaging size 60
ATC code J05AE
ATC description DIRECT ACTING ANTIVIRALS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-04-08
Estimated end date 2020-07-31
Actual end date 2020-07-22
Shortage status Resolved
Updated date 2020-07-23
Company comments Allocating to 100% of our market.
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v12 2020-07-23 French Compare
v11 2020-07-23 English Compare
v10 2020-06-04 French Compare
v9 2020-06-04 English Compare
v8 2020-05-14 French Compare
v7 2020-05-14 English Compare
v6 2020-05-08 French Compare
v5 2020-05-08 English Compare
v4 2020-05-01 French Compare
v3 2020-05-01 English Compare
v2 2020-04-10 French Compare
v1 2020-04-10 English Compare

Showing 1 to 12 of 12